Clinical Trials Logo

Glomerulonephritis, IGA clinical trials

View clinical trials related to Glomerulonephritis, IGA.

Filter by:

NCT ID: NCT02187900 Recruiting - IgA Nephropathy Clinical Trials

Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f.

Start date: June 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to determine whether Multi-glycoside of Tripterygium Wilfordii HOOK. f. is effective and safe in the treatment of IgA nephropathy.

NCT ID: NCT02160132 Recruiting - Clinical trials for Glomerulonephritis, IGA

A Controlled Study of Steroids Therapy for Patients of IgA Nephropathy With Active Pathological Changes.

Start date: June 2014
Phase: Phase 2
Study type: Interventional

This prospective, randomized, controlled, multi-center clinical trial will evaluate the effect and security of steroids therapy for patients of IgA nephropathy with active pathological changes,including crescents,necrosis and microthrombus.

NCT ID: NCT02112838 Completed - IGA Nephropathy Clinical Trials

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

Start date: October 2014
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine whether fostamatinib is safe and effective in the treatment of IgA Nephropathy

NCT ID: NCT02062684 Completed - IgA Nephropathy Clinical Trials

BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration

Start date: June 2013
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of subcutaneous blisibimod administration in addition to standard therapy in patients with biopsy proven IgA Nephropathy with persistent proteinuria of between 1-6 g/day.

NCT ID: NCT02052219 Withdrawn - IgA Nephropathy Clinical Trials

BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy

Start date: October 2014
Phase: Phase 3
Study type: Interventional

The purpose of this study is to compare the effect of blisibimod plus standard of care versus placebo plus standard of care alone on the proportion of subjects achieving improvement in renal disease parameters.

NCT ID: NCT01879514 Recruiting - IgA Nephropathy Clinical Trials

Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath

Start date: January 2010
Phase: N/A
Study type: Interventional

IgA nephropathy(IgAN) is the highest incidence of kidney pathology in the primary nephropathy. In terms of differences in prognosis, severe IgA nephropathy,one of the most main primary renal disease,could cause the uremia. It will be significant that early indicators of prognosis and early intervention can be normalized and the scientific criteria for judging the efficacy of great clinical can be established. The subject based on the past study,literature research and various treatment will take the method of multi-center, double-blind, randomized, control to investigate the standard treatment of severe IgA nephropathy. Otherwise the uniformity and objectivity of Traditional Chinese Medicine (TCM) will be improved by the standardization of TCM research based on the epidemiological investigation and statistical analysis. The subject will determine the efficacy of more sensitive biomarkers and establish more scientific criteria for judging the effect with the application of urine proteomics and metabolomics technologies in order to operate in the formation of the standardization program of the treatment of severe IgA nephropathy with the Integrative medicine of TCM.

NCT ID: NCT01854814 Completed - IgA Nephropathy Clinical Trials

The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Patients

MAIN
Start date: July 2013
Phase: N/A
Study type: Interventional

The study is to evaluate the effect of Mycophenolate Mofetil compared with losartan alone on time to doubling of serum creatinine or the onset of end stage renal disease in patients with advanced IgA nephropathy who are treated with the maximal tolerated daily dose of losartan.The study will also assess the effects of MMF compared with losartan alone on the changes of urine albumin excretion and the changes in estimated glomerular filtration rate.

NCT ID: NCT01838239 Completed - Healthy Subjects Clinical Trials

Development of a Metabolic Assessment Tool for Chronic Kidney Disease

Start date: June 2008
Phase: N/A
Study type: Interventional

The purpose of this study is to examine the variation between individuals in blood lipid metabolites, and the changes in these metabolites in response to omega-3 fatty acids in patients with immunoglobulin A nephropathy (IgAN) and in healthy subjects. The hypothesis is that measuring variation among individuals and changes in response to omega-3 fatty acids comprehensively by using metabolomics will help to identify those individuals who are responders and those who are non-responders to omega-3 fatty acids as an anti-inflammatory intervention.

NCT ID: NCT01802034 Recruiting - Kidney Diseases Clinical Trials

Repository of Novel Analytes Leading to Autoimmune, Inflammatory and Diabetic Nephropathies (RENAL AID)

RENAL AID
Start date: February 2013
Phase:
Study type: Observational [Patient Registry]

A central goal of this data repository is to collect data from a large population of subjects with a variety of renal disease states. Cohorts will include subjects with diabetes, inflammatory/autoimmune and transplant related renal conditions. Additionally, the repository will have the capacity to store biospecimens and electronic data in control subjects without established renal disease. This initiative will provide an opportunity to compare data from various disease states and controls with the objective of determining clinical and biological factors that predict disease progression, response to therapy and identify discriminating noninvasive clinical and biological features that predict renal biopsy findings.

NCT ID: NCT01781312 Not yet recruiting - IgA Nephropathy Clinical Trials

Probiotics in IgA Nephropathy

Start date: January 2013
Phase: N/A
Study type: Interventional

Recent studies have shown an increased gastrointestinal reactivity and increased intestinal permeability in IgA nephropathy (IgAN). Probiotic supplementation is known to impact the gastrointestinal immune system possibly by improvement of both the immunologic and the non-immunologic intestinal barrier. Probiotic supplementation should thus theoretically have an effect on IgAN. In this study the investigators will study the efficacy and safety of Lactobacillus reuteri.